Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Terns Pharmaceuticals Raises $87M in Series C

2021-01-06
FOSTER CITY, CA, Terns Pharmaceuticals has closed an $87 million Series C financing led by Deerfield Management Company.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, has closed an $87 million Series C financing. The financing round was led by Deerfield Management Company alongside a strategic equity investment by Eli Lilly and Company with participation from OrbiMed Advisors, Lilly Asia Ventures, Vivo Capital, Samsara Capital, Suvretta Capital Management and several other new investors.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns' programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors